Science for a better life

Investor News 2004

1 - 10

11 - 20

21 - 30

31 - 40

41 - 50

51 - 60

October 29, 2004

LANXESS received investment grade status

more

October 27, 2004

FDA Grants Orphan Drug Designation to BAY 43-9006 for the Treatment of Renal Cell Carcinoma

more

October 25, 2004

Bayer HealthCare / Onyx Pharmaceuticals

Bayer and Onyx Announce Positive Phase II Data in Patients with Advanced Kidney Cancer

more

October 15, 2004

KOGENATE® Bayer with BIO-SET® Approved by European Union Commission, Sets New Standard in Patient Safety and Convenience

more

October 13, 2004

Bayer reaches agreement with U.S. Department of Justice in acrylonitrile-butadiene rubber investigation

more

October 08, 2004

Package of measures to yield annual savings of EUR 200 million from 2007:

Bayer CropScience confirms profitability targets

more

October 06, 2004

Spin-Off Report published:

Bayer sets allotment ratio for Lanxess shares at 10 to 1

more

September 30, 2004

Bayer Corporation reaches agreement with U.S. Department of Justice in polyester polyols investigation

more

September 29, 2004

Bayer and Onyx Announce Phase II Results of Treatment with BAY 43-9006 In Patients with Advanced Primary Liver Cancer

more

September 13, 2004

Further step in the realignment of Bayer HealthCare:

Bayer enters strategic pharmaceuticals alliance with Schering-Plough

more

1 - 10

11 - 20

21 - 30

31 - 40

41 - 50

51 - 60

Services

Last updated: December 06, 2013